Tag Archives: Renaissance Capital

IPOs keep their hopes alive with new registrations

Unfazed by record government shutdown, 2019 healthcare IPOs burst out of the gate with 1 pricing and 5 filings. As expected, no IPOs priced this past week. And due to… Read more »

Five more biotechs and one device maker close out 3rd quarter IPOs this week.

There are as many as five more biotech IPOs and one medical device maker pricing this week, raising up to $535 million. Even if two are postponed, it will still… Read more »

Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »

Healthcare IPOs sputter as uncertainty, anxiety cloud–everything; what is an issuer and investor to do?

Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »